The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada

Journal of Medical Virology

Volumn 90, Issue 3, 2018, Pages 592-598

  Steben, Marc ^a   Ouhoummane, Najwa ^a   Rodier, Caroline ^b   Sinyavskaya, Liliya ^c   Brassard, Paul ^c  

^a INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^b Merck Canada Inc   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

anogenital warts; condyloma; epidemiology; HPV vaccine; human papillomavirus

Indexed keywords

ANTIVIRUS AGENT; WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE; CANADA; CHILD; CONDYLOMA ACUMINATUM; FEMALE; HERD IMMUNITY; HUMAN; INCIDENCE; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PREVENTIVE HEALTH SERVICE; QUEBEC; SEX FACTOR; VACCINATION; VERRUCA VULGARIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ANTIVIRAL AGENTS; CANADA; CHILD; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; INCIDENCE; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUEBEC; SEX FACTORS; VACCINATION; WARTS; YOUNG ADULT;

EID: 85033587200     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24968     Document Type: Article

References (32)

1. de Sanjose S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007; 7:453–459.
2. Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016; 4:e453––e463.
3. Report of the meeting on HPV Vaccine coverage and impact monitoring, 16– 17 November 2009, Geneva, Switzerland. 2010, World Health Organization (WHO).
4. Goggin, P, Coutlée F, Defay F, et al. Prevalence of genital HPV infection in women aged 17–29 in the post-vaccinated period, Québec, Canada in European Research Organization on Genital Infection and Neoplasia (EUROGIN). 2015: Seville, Spain.
5. Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014; 110:2804–2811.
6. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, national health and nutrition examination surveys, 2003–2010. J Infect Dis. 2013; 208:385–393.
7. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 2013; 32:26–32.
8. Tabrizi SN, Brotherton JLM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012; 206:1645–1651.
9. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (Types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009; 199:805–814.
10. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol. 1995; 33:2058–2063.
11. Drolet M, Brisson M, Maunsell E. The impact of anogenital warts on health-Related quality of life: a 6-Month prospective study. Sex Transm Dis. 2011; 38:949–956.
12. Pirotta M, Ung L, Stein A, et al. The psychosocial burden of human papillomavirus related disease and screening interventions. Sex Transm Infect. 2009; 85:508–513.
13. Steben M, LaBelle D. Genital warts: canadians' perception, health-related behaviors, and treatment preferences. J Low Genit Tract Dis. 2012; 16:409–415.
14. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013; 346:p.f2032–p.f2032.
15. Baandrup L, Blomberg M, Dehlendorff C, et al. Significant decrease in the incidence of genital warts in young danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013; 40:130–135.
16. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of california public family planning administrative claims data, 2007–2010. Am J Public Health. 2012; 102:833–835.
17. Leval A, Herweijer E, Arnheim-Dahlström L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012; 206:860–866.
18. Mikolajczyk RT, Kraut AA, Horn J, et al. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany—An ecologic study. Sex Transm Dis. 2013; 40:28–31.
19. Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J. 2011; 124:51–58.
20. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015; 15:565–580.
21. Guerra FM, Roselia LC, Dunn S, et al. Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): a population-based assessment. Vaccine 2016; 34:4678–4683.
22. Kliever E, Demers AA. Quadrivalent HPV vaccination and the incidence of anogenital warts in Manitoba, Canada in 28th International Papillomavirus Conference and Clinical and Public Health worshops. 2012: Puerto Rico.
23. Smith LM, Strumpf EC, Kauffman JS, et al. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. Pediatrics 2015; 135:e1131–e1140.
24. Sauvageau C, Gilca V. La vaccination des pré-adolescents contre les virus du papillome humain (VPH) au Québec: deux ou trois doses? Comité de l'immunisation du Québec, Institut national de santé publique du Canada, 2013: p. 73 pages.
25. MSSS, Flash Vigie [Internet]. Available from: http://publications.msss.gouv.qc.ca/msss/fichiers/flashvigie/06-271-02W-vol8_no7.pdf,2013
26. Guay M, Clément P, Hamid A, et al., Institut national de santé publique du Québec. Évaluation de l'implantation du Programme de vaccination contre les virus du papillome humain (VPH) chez les adolescentes du Québec [Internet]. Montréal, Québec. Available from: https://www.inspq.qc.ca/pdf/publications/1561_EvalImplanProgVaccVPHAdoQc.pdf,2013
27. Steben M, Ouhoummane N, Rodier C, et al. Temporal trends in genital warts among individuals covered by the public prescription drug insurance plan in the province of quebec, Canada, from 1998 to 2007. J Low Genit Tract Dis. 2013; 17:147––153.
28. Kliewer EV, Demers AA, Elliott L, Lotocki R, Butler JR, Brisson M. Twenty-Year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Infect. 2009; 36:380–386.
29. Marra F, Ogilvie G, Colley L, et al. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect. 2008; 85:111–115.
30. Brisson M, van de Velde N, Franco EL, et al. Incremental impact of adding boys to current human papillomavirus accination programs: role of herd immunity. J Infect Dis. 2011; 204:372–376.
31. Read TRH, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011; 87:544–547.
32. Perkins RB, Legler A, Hanchate A. Trends in male and female genital warts among adolescents in a safety-net health care system 2004-2013: correlation with introduction of female and male male human papillomavirus vaccination. Sex Transm Dis. 2015; 42:665–668.